November 23, 2024
1 min read
November is Pancreatic Cancer Awareness Month.
The observance is intended to raise awareness about the disease and the need for more effective therapies.
Pancreatic cancer research advances include better understanding of the potential benefits of transvascular energy, a ketogenic diet and surveillance of individuals at high risk for the disease. Image: Adobe Stock
In conjunction with the observance, Healio presents 12 updates in pancreatic cancer research and treatment.
1. The delivery of transvascular energy reduced pain and improved quality of life within 7 days among patients with pancreatic cancer. The approach also reduced demand for opioids. Read more.
2. An analysis of adults with obesity showed those who underwent bariatric surgery had reduced risk for pancreatic cancer. Read more.
3. Nearly 80% of individuals clinically diagnosed with stage I pancreatic ductal adenocarcinoma and close to 30% diagnosed with stage II disease got upstaged after surgery. Read more.
4. The combination of a ketogenic diet and an experimental MNK inhibitor may be able to shrink pancreatic cancer tumors, according to preliminary study findings. Read more.
5. The addition of comprehensive metastasis-directed radiation therapy to chemotherapy improved outcomes for patients with oligometastatic pancreatic ductal adenocarcinoma. Read more.
6. Surveillance of individuals at a high risk for pancreatic ductal adenocarcinoma led to the detection of smaller, earlier-stage tumors. Read more.
7. The microbiome profile of early-onset pancreatic adenocarcinoma is distinct from that of average-onset disease, according to findings presented at ASCO Annual Meeting. Read more.
8. An AI-guided navigation workflow helped identify patients earlier in the diagnostic timeline than the traditional cancer referral process while reducing times to biopsy, follow-up and treatment initiation. Read more.
9. Greater utilization of genetic testing among men could have considerable benefits with regard to detection, risk management and personalized treatment of cancers. Read more.
10. Patients with type 2 diabetes on glucagon-like peptide-1 receptor agonists had significantly lower risk for pancreatic cancer compared with those on other antidiabetic therapies, regardless of weight. Read more.
11. The mortality rate among patients hospitalized for acute pulmonary embolism with pancreatic cancer declined between 2001 and 2020. Read more.
12. Changes in body composition and biochemical markers can be detected in the 36 months prior to diagnosis of pancreatic ductal adenocarcinoma. These changes may serve as potential biomarkers for early cancer detection. Read more.
